---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-016110"
form_type: "8-K"
ticker: "ABPO"
cik: "0001893219"
company_name: "Abpro Holdings, Inc."
filed_at: "2025-02-21T23:59:59+00:00"
generated_at: "2026-05-26T07:17:45.325707+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Abpro provides pipeline update; Celltrion partnership for ABP-102 fully funded with up to $1.75B milestones

## Summary
- Celltrion funds all development of ABP-102 (HER2/CD3 T-cell engager) for breast/gastric cancer; Abpro retains 50% profit share.
- ABP-201 (VEGF/ANG2) for Wet AMD/DME: IND filing expected Q1 2026, Phase 1 start same year.
- ABP-102 IND filing targeted for 2H 2025; Phase 1 initiation in 1H 2026.
- Additional pipeline: ABP-150 (Claudin18.2/CD3) and ABP-110 (GPC3/CD3) IND filings in 2026, Phase 1 in 2027.
- No financial results; presentation highlights platform, preclinical data, and upcoming milestones.

## SEC filing metadata
- accession: 0001213900-25-016110
- form_type: 8-K
- ticker: ABPO
- cik: 0001893219
- company_name: Abpro Holdings, Inc.
- filed_at: 2025-02-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1893219/000121390025016110/0001213900-25-016110-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1893219/000121390025016110/ea0231728-8k_abpro.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-016110
- JSON: https://secwatch.observer/filing/0001213900-25-016110.json
- Plain text: https://secwatch.observer/filing/0001213900-25-016110.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.